Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States.
Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Company profile from EODHD, stored Nov 2, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | $135.6K | +1,969.7% | -69.3% | -$3.2M | -$5.2M |
| Mar 2026filed May 14, 2026 | — | — | — | — | — |
| Dec 2025filed Mar 31, 2026 | $27.0K | -93.2% | 20.0% | -$2.9M | $719.2K |
| Sep 2025filed Nov 14, 2025 | $15.6K | -96.3% | 20.0% | -$3.3M | -$4.6M |
| Jun 2025filed Aug 18, 2025 | $6.6K | -98.9% | 20.0% | -$3.5M | -$1.9M |
| Mar 2025filed May 15, 2025 | $5.1K | -99.6% | 20.0% | -$2.0M | -$2.2M |
| Dec 2024filed Mar 28, 2025 | $394.8K | -70.2% | 20.0% | -$3.2M | -$3.4M |
| Sep 2024filed Nov 14, 2024 | $426.4K | -50.0% | 20.0% | -$3.7M | -$3.9M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched HCWB. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
37,709 shares short
-23,232 shares (-38.1%) vs Sep 30, 2026
2.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
60,941 shares short
+51,667 shares (+557.1%) vs Sep 15, 2026
3.7% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
9,274 shares short
-24,862 shares (-72.8%) vs Aug 31, 2026
1% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
34,136 shares short
+19,788 shares (+137.9%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
14,348 shares short
-6,631 shares (-31.6%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
20,979 shares short
-8,981 shares (-30%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind HCWB’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
1 for 6 · reverse split
Effective Jun 30, 2026
Each 6 pre-split shares become 1 post-split share.
Source: EODHD
1 for 40 · reverse split
Effective Apr 11, 2025
Each 40 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if HCWB is in your portfolio and how much it contributes.
Sign inLoading market dates
2 smart-money holders: institutions with a high Holder IQ
Sentiment: unknown
No recent insider trades detected.
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
12 filers reported a long position in HCWB for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
100%
of the 103.5K shares 13-F filers reported
Moves vs Q1 2026
5 added3 trimmed
2 new
Net shares held
+73.6%
across the 8 holders with a comparable Q1 2026 book
Q1 2026 shares are adjusted for the 2026-06-30 1-for-6 reverse split.
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | $260.2K · 52.1K shares | 52.1K | +2,113.3% |
| 2 | CITADEL ADVISORS LLC | $99.5K · 19.9K shares | 19.9K | +358.7% |
| 3 | HRT FINANCIAL LP | $67K · 13.6K shares | 13.6K | -69.4% |
| 4 | VANGUARD FIDUCIARY TRUST CO | $32.5K · 6.5K shares | 6.5K | +1,952.5% |
| 5 | Tower Research Capital LLC (TRC) | $20.5K · 4.1K shares | 4.1K | +66.5% |
| 6 | Connective Capital Management, LLC | $16.7K · 3.3K shares | 3.3K | New |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $10K · 2K shares | 2K | 0% |
| 8 | Golden State Wealth Management, LLC | $8.3K · 1.7K shares | 1.7K | 0% |
| 9 | BARCLAYS PLC | $953 · 191 shares | 191 | New |
| 10 | OSAIC HOLDINGS, INC. | $20 · 4 shares | 4 | -7.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inUnlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.